Women of childbearing age should use contraception while on tirzepatide and discontinue the medication at least 2 months before attempting conception to allow complete washout given the long half-life
The Route of Administration The most significant barrier is that hydroxocobalamin is licensed for parenteral administrationmeaning it must be given by injection (Intramuscular, IM)
Important: B12 injections are not intended to diagnose, treat, cure, or prevent disease
Based on the clinical evidence and the patient profiles where the compound appears most applicable, the following characteristics tend to describe good candidates for AOD 9604 evaluation when it is medically supervised: Patients with stubborn localized fat deposits that have not responded to diet and exercise, particularly visceral and lower abdominal fat Patients who cannot tolerate GLP-1 medications due to nausea, gastrointestinal side effects, or contraindications Active patients with reasonable baseline metabolic health who want a targeted lipolytic tool to complement their training and nutrition program Patients already on a peptide protocol who want to add a fat-targeting element to a GHK-Cu, NAD+, or sermorelin stack Patients who are not candidates for stimulant-based fat loss medications due to cardiovascular sensitivity, anxiety, or blood pressure concerns AOD 9604 is not appropriate as a standalone weight loss strategy for patients with significant obesity, insulin resistance, or metabolic syndrome
We watch for signs like less fatigue, better nerve function, and overall health
